BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• 

  Adcomms

  FDA Adcomm Calls for Changes in Perioperative Lung Cancer Trials

  The FDA’s Oncologic Drugs Advisory Committee on Thursday strongly supported changing clinical trials for non-small cell lung cancer drugs given in the perioperative setting, pointing out the need for a more nuanced approached to treatments before and after surgery.

  July 26, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Weight loss

  Roche to Accelerate Development of Obesity Assets from $2.7B Carmot Buy

  Encouraged by the potential of the weight-loss candidates acquired from Carmot Therapeutics, Roche will speed up the development of its obesity programs, seeking to differentiate itself in the market.

  July 26, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Argenx’s Strong Q2 Sales Reinvigorate Clinical Plans for Vyvgart

  The company’s FcRn inhibitor Vyvgart grew 17% quarter-over-quarter, reigniting confidence it will hit its ambitious goals despite a string of clinical setbacks in recent months.

  July 26, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug pricing

  Big Pharma Appears to Be Unfazed by IRA Drug Price Negotiations

  Despite their initial kicking and screaming, drugmakers seem confident the Inflation Reduction Act’s Medicare Drug Price Negotiation Program will not greatly impact their bottom lines.

  July 26, 2024

   · 

  2 min read

   · 

  Greg Slabodkin
• 

  Regulatory

  EU Regulatory Panel Recommends Against Approval of Eisai, Biogen’s Leqembi for Alzheimer’s

  The European Medicines Agency’s Committee for Medicinal Products for Human Use found that Leqembi’s benefits do not outweigh the risks of severe side effects associated with the treatment.

  July 26, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Earnings

  BMS Gets Q2 Beat, Raises Full-Year Guidance as Cost-Cutting Initiative Continues

  Bristol Myers Squibb on Friday reported strong second-quarter results, led by the blood thinner Eliquis and cancer therapy Opdivo, as it looks to cut $1.5 billion in costs by 2025.

  July 26, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Sharps Technology Enters Into a Five-Year Sales Agreement with Strategic U.S. Medical Products Company Creating +$5O Million in New Revenue for EU Facility

  July 26, 2024

   · 

  5 min read
• Press Releases

  Positron Corporation Introduces New, Advanced Designed, Economically Priced PET-CT

  July 26, 2024

   · 

  6 min read
• Press Releases

  Intuitive President David J. Rosa Appointed to Intuitive Board of Directors

  July 26, 2024

   · 

  2 min read
• Press Releases

  European regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events

  July 26, 2024

   · 

  5 min read